REG - Arecor Therapeutics - Grant of Options and PDMR Dealing
04/06/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250604:nRSD3734La&default-theme=true
RNS Number : 3734L Arecor Therapeutics PLC 04 June 2025
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
GRANT OF OPTIONS AND PDMR DEALING
Cambridge, UK, 4 June 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that on 2 June 2025 the Company granted a total of 295,000
options under the Company's Long Term Incentive Plan ("LTIP Options") and
239,600 options under the Company's All Employee Share Ownership Plan ("AESOP
Options"), over new ordinary shares of 1 pence each in the Company ("Ordinary
Shares").
Details of options granted to PDMRs are included in the table below.
Type Name of individual Job title Number of share options granted under 2025 award Price (£)
LTIP Sarah Howell Chief Executive Officer 125,000 0.01
AESOP Sarah Howell Chief Executive Officer 66,000 £0.435
LTIP Jan Jezek Chief Scientific Officer 85,000 0.01
AESOP Jan Jezek Chief Scientific Officer 26,000 £0.435
LTIP David Gerring Chief Development Officer 85,000 0.01
AESOP David Gerring Chief Development Officer 26,000 £0.435
The LTIP Options have an exercise price of 1 pence. Performance conditions
include both time (30% of the options granted) and Share Price Outperformance*
(70% of the options granted) during the three-year performance period. The
LTIP Options are subject to continued service and the extent to which the
performance conditions are satisfied. Vesting does not occur until the end of
the three-year performance period. Vested LTIP Options will normally be
exercisable from after the end of the three-year performance period and until
the tenth anniversary of the grant date, after which time they will lapse if
not exercised. They are subject to a condition that the LTIP Options or the
Ordinary Shares acquired on exercise of the LTIP Options (other than those
sold to cover tax and National Insurance) are held for a minimum one-year
period from vesting.
*Outperformance when compared to the FTSE AIM All Share index.
The AESOP Options vest after 36 months and are exercisable at £0.435 per
share, being the closing market price of an Ordinary Share on the day
preceding the date of grant. The AESOP Options are subject to continuous
employment and are exercisable from after the end of the 36 months until the
tenth anniversary of the date of grant, after which date the option will lapse
if not exercised. The grant of AESOP Options included 118,000 AESOP Options
granted to certain PDMRs.
The notifications below, made in accordance with the requirements of the
Market Abuse Regulation, provide further detail.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com (mailto:info@arecor.com)
David Ellam, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com (mailto:info@arecor.com)
Singer Capital Markets Advisory LLP (NOMAD and Broker)
Phil Davies, Sam Butcher Tel: +44 (0) 20 7496 3000
ICR Healthcare
Chris Gardner, David Daley, Lindsey Neville Tel: +44 (0) 20 3709 5700
Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio. For further details please see our website, www.arecor.com
(http://www.arecor.com)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Sarah Howell
2. Reason for the notification
a) Position/status: Chief Executive Officer and Executive Director
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan.
c) Price(s) and volume(s): 2025 LTIP Award
Exercise Price(s) (£) Volume(s)
£0.01 125,000
d) Aggregated information:
· Aggregated volume: 125,000
· Price: £0.01
e) Date of the transaction: 2 June 2025
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
125,000
£0.01
e)
Date of the transaction:
2 June 2025
f)
Place of the transaction:
Outside of a trading venue
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Sarah Howell
2. Reason for the notification
a) Position/status: Chief Executive Officer and Executive Director
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of awards over Ordinary Shares under the Company's All Employee Share
Ownership Plan.
c) Price(s) and volume(s): 2025 AESOP Award
Exercise Price(s) (£) Volume(s)
£0.435 66,000
d) Aggregated information:
· Aggregated volume: 66,000
· Price: £0.435
e) Date of the transaction: 2 June 2025
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
66,000
£0.435
e)
Date of the transaction:
2 June 2025
f)
Place of the transaction:
Outside of a trading venue
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Jan Jezek
2. Reason for the notification
a) Position/status: Chief Scientific Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan
c) Price(s) and volume(s): 2025 LTIP Award
Exercise Price(s) (£) Volume(s)
£0.01 85,000
d) Aggregated information:
· Aggregated volume: 85,000
· Price: £0.01
e) Date of the transaction: 2 June 2025
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
85,000
£0.01
e)
Date of the transaction:
2 June 2025
f)
Place of the transaction:
Outside of a trading venue
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: Jan Jezek
2. Reason for the notification
a) Position/status: Chief Scientific Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of awards over Ordinary Shares under the Company's All Employee Share
Ownership Plan.
c) Price(s) and volume(s): 2025 AESOP Award
Exercise Price(s) (£) Volume(s)
£0.435 26,000
d) Aggregated information:
· Aggregated volume: 26,000
· Price: £0.435
e) Date of the transaction: 2 June 2025
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
26,000
£0.435
e)
Date of the transaction:
2 June 2025
f)
Place of the transaction:
Outside of a trading venue
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: David Gerring
2. Reason for the notification
a) Position/status: Chief Development Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of awards over Ordinary Shares under the Company's Long Term Incentive
Plan.
c) Price(s) and volume(s): 2025 LTIP Award
Exercise Price(s) (£) Volume(s)
£0.01 85,000
d) Aggregated information:
· Aggregated volume: 85,000
· Price: £0.01
e) Date of the transaction: 2 June 2025
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
85,000
£0.01
e)
Date of the transaction:
2 June 2025
f)
Place of the transaction:
Outside of a trading venue
Details of the person discharging managerial responsibilities/person closely
associated
a) Name: David Gerring
2. Reason for the notification
a) Position/status: Chief Development Officer
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name: Arecor Therapeutics plc
b) LEI: 98450093D12I3A8DDD58
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Ordinary shares of 1 pence each
Identification code: GB00BMWLM973
b) Nature of the transaction: Grant of awards over Ordinary Shares under the Company's All Employee Share
Ownership Plan.
c) Price(s) and volume(s): 2025 AESOP Award
Exercise Price(s) (£) Volume(s)
£0.435 26,000
d) Aggregated information:
· Aggregated volume: 26,000
· Price: £0.435
e) Date of the transaction: 2 June 2025
f) Place of the transaction: Outside of a trading venue
d)
Aggregated information:
· Aggregated volume:
· Price:
26,000
£0.435
e)
Date of the transaction:
2 June 2025
f)
Place of the transaction:
Outside of a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHPKQBKPBKKOAKRecent news on Arecor Therapeutics
See all newsREG - Arecor Therapeutics - Grant of Options and PDMR Dealing
AnnouncementREG - Arecor Therapeutics - Result of AGM
AnnouncementREG - Arecor Therapeutics - Non-Executive Director Board Change
AnnouncementREG - Arecor Therapeutics - Director/PDMR Dealing
AnnouncementREG - Arecor Therapeutics - Arecor Partnership with Skye Bioscience
Announcement